Clinical Trial Update: An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of BMS-986178 alone or with nivolumab and/or ipilimumab in advanced or metastatic solid cancers completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• BMS 986178
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Advanced Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-01-25